Form 4: Ironwood Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Michael Shetzline, SVP, CMO, Head-Res&Drug at Ironwood Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On February 10, 2025, Michael Shetzline, an executive at Ironwood Pharmaceuticals, acquired 133,333 shares of Class A Common Stock at $0.
• On the same day, Shetzline sold 41,269 shares of Class A Common Stock at an average price of $1.76, with prices ranging from $1.60 to $1.84.
• The sale was to cover tax withholding obligations related to the vesting of restricted stock units and performance-based restricted stock units.
• Following the reported transactions, Shetzline beneficially owns 554,007 shares of Class A Common Stock.
• Shetzline has granted power of attorney to several individuals to execute filings with the SEC.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock transactions for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares, but it is primarily driven by tax obligations.

Key Dates

Keywords

Form 4, Ironwood Pharmaceuticals, Michael Shetzline, Stock Sale, Tax Obligations, Restricted Stock Units, Beneficial Ownership, Power of Attorney, SEC Filing